Buffered microencapsulated compositions and methods
A microcapsule composition comprising at least one polymer substantially disposed as a semi-permeable shell around a buffered solution and at least one therapeutic agent, wherein the therapeutic agent permeates the shell, and wherein the composition is suitable for topical epithelial cells of mammal.
1. A topical microcapsule composition comprising: a plurality of microcapsules and a carrier, each of said microcapsules comprising at least one amphiphilic polyurethane polymer substantially disposed as a semi-permeable shell around a buffered solution, said microcapsule composition comprising at least a first subset of microcapsules, wherein the first subset of microcapsules comprises within each said microcapsules, a therapeutic agent for topical use on epithelial tissue; wherein the therapeutic agent permeates the shell.
2. The microcapsule composition of claim 1 , wherein the buffered solution is an aqueous solution.
3. The microcapsule composition of claim 1 , wherein the therapeutic agent is selected from the group consisting of antibacterial agents, antifungal agents, benzoyl peroxide, coal tar, corticosteroids, retinoids, salicyclic acid, antiviral agents, immunosuppressants, and biologic agents for treating psoriasis.
4. The microcapsule composition of claim 1 , wherein the composition is a moisturizer, cream, lotion, foam, gel, shampoo, hair conditioner, hair gel, or a nail polish.
5. The microcapsule composition of claim 1 , wherein the molecular weight of the polymer is from about 1,000 to about 20,000 g/mole.
6. The microcapsule composition of claim 1 , wherein the polymer is cross-linked.
7. The microcapsule composition of claim 1 , wherein the microcapsule has a diameter of from about 1 micron to about 3 mm.
8. The microcapsule composition of claim 1 , further comprising a second subset of microcapsules, wherein each of said second subset of microcapsules comprises, a second therapeutic agent in a buffered solution and encapsuled within a semi-permeable shell, wherein the second therapeutic agent permeates the semi-permeable shell, and wherein the composition is suitable for delivery to a mammal.
9. The microcapsule composition of claim 8 , wherein the first subset of microcapsules has a therapeutic agent release profile that differs from the therapeutic agent release profile of the second subset of microcapsules.
10. The microcapsule composition of claim 1 , wherein the microcapsule is made of a polymeric system that undergoes a sol-gel transition once administered.
11. The microcapsule composition of claim 1 , wherein the microcapsule is biodegradeable.
12. The microcapsule composition of claim 1 , wherein the therapeutic agent is an antifungal agent selected from the group consisting of: amphotericin B, candicidin, filipin, hamycin, natamycin, nystatin, rimocidin; imidazole, triazole, thiazole, bifonazole, butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, albaconazole, fluconazole, isavuconazole, itraconazole, posaconazole, ravuconazole, terconazole, voriconazole, abafungin; ecninocandins, anidulafungin, caspofungin, and micafungin.